Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on October 30, 2019. The company is incorporated in Nevada and its common stock and warrants trade on The Nasdaq Capital Market under the symbols "CTXR" and "CTXRW," respectively.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
On October 30, 2019, the Company received written notice from The Nasdaq Stock Market indicating noncompliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)). This noncompliance is due to the closing bid price of the Company's common stock falling below $1.00 per share for 30 consecutive business days.
- Immediate Effect: The notification has no immediate effect on the listing or trading of the Company's securities.
- Compliance Period: The Company has an initial 180-day compliance period ending April 27, 2020.
- Requirement to Cure: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to April 27, 2020.
Outlook, Risks, and Management Commentary
Management intends to consider all available alternatives to regain compliance with the minimum bid price requirement. If the Company fails to regain compliance by April 27, 2020, it may be eligible for an additional 180-day grace period, provided it meets other initial listing standards (excluding the bid price) and notifies Nasdaq of its intent to cure. Failure to cure the deficiency or qualify for an extension may result in delisting. The Company retains the right to appeal a delisting determination, during which time the stock would remain listed.
Key Facts for Investor Verification
- Verify the current closing bid price of CTXR to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor the Company's announcements regarding potential reverse stock splits or other corporate actions intended to increase the share price.
- Check for any subsequent filings regarding the Company's eligibility for a second compliance period if the initial deadline is missed.
- Review the Company's broader financial health in recent 10-Q or 10-K filings, as this 8-K does not contain financial performance data.